Arctic Bioscience – Q3 2023 Operational update – More than 50% recruited in the phase IIb HeROPA clinical trial
Highlights Q3 2023: · Good progress in patient recruitment for the phase IIb HeROPA clinical trial, more than 50% recruited · New findings on the positive effects of Herring Roe Oil on psoriasis published in September · A good financial situation with a total available liquidity position of NOK 126,5 million at the end of the quarter, the establishment of a credit facility has improved available liquidity · Revenues from nutraceutical products was a bit slow compared to Q3 last year – with some deliveries being pushed into Q4 and possibly postponed to 2024 · Positive gross